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It has long been noticed that the efficacy observed in small
early phase studies is generally better than that observed in
later larger studies. Historically, the inflation of the efficacy
results from early proof-of-concept studies is either ignored,
or adjusted empirically using a frequentist or Bayesian ap-
proach. In this article, we systematically explained the un-
derlying reason for the inflation of efficacy results in small
early phase studies from the perspectives of measurement
errormodels and selection bias. A systematic methodwas
built to adjust the early phase study results from both fre-
quentist and Bayesian perspectives. A hierarchical model
was proposed to estimate the distribution of the efficacy
for a portfolio of compounds, which can serve as the prior
distribution for the Bayesian approach. We showed through
theory that the systematic adjustment provides an unbiased
estimator for the truemean efficacy for a portfolio of com-
pounds. The adjustment was applied to paired data for the
Abbreviations: ABC, a black cat; DEF, doesn’t ever fret; GHI, goes home immediately.
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efficacy in early small and later larger studies for a set of
compounds in diabetes and immunology. After the adjust-
ment, the bias in the early phase small studies seems to be
diminished.
K E YWORD S
Selection bias, measurement error, discount, Bayesian hierarchical
model
1 | INTRODUCTION
Clinical development of a new treatment is a lengthy, rigorous, and very costly process. Each treatment generally goes
through a stage-wise procedure before regulatory approval into themarket. Generally, research begins with smaller
exploratory studies and gradually moves to larger confirmatory studies. It has been increasingly recognized that early
phase trials can not only provide safety assessments, but also have the potential to evaluate the efficacy signal. Sponsors
tend to only select compounds that show promising efficacy (e.g. meeting a certain threshold value δ) and a reasonable
safety profile in smaller early studies tomove into the next stage of development. It is not uncommon to see compounds
selected in a smaller study show poor efficacy results in a subsequent larger study.
In a phase 2 study, anifrolumab showed an impressive improvement in systemic lupus erythematosus (SLE) respon-
der index 4 (SRI4) at 52 weeks compared to placebo (62.6% for anifrolumab 300mg vs. 40.2% for placebo; p<0.001)[1].
However, recently 2 phase 3 studies showed less impressive results. In TULIP-1 Study, the response rates were 36.2%
for anifrolumab 300 mg vs. 40.4% for placebo [2]. In TULIP-2 Study, the response rates were 55.5% and 37.3% for
anifrolumab 300 mg and placebo treatments, respectively (p < 0.001) [3]. The first study did not reach statistical
significance and neither study achieved themagnitude of the treatment effect as observed in the phase 2 study. No
clear differences in the study design and study population could explain the sharp contrast of results between the phase
2 study and the first 3 study.
The average cost of developing a new drug that gains marketing approval is estimated to be $1 to $2.6 billion [4, 5].
To improve efficiency, the most critical factor is to improve the probability of success for phase 2 and 3 development [6].
Therefore, characterizing a statistical framework that can explain the abovementioned “sharp contrast" helps enhance
quantitative decision-making during the stage-wise drug development process.
The terminology of the proof-of-concept (PoC) study we use in the article is relative: depending on the endpoints,
for some therapeutic areas, a dose-response phase 2 studymay be considered a PoC study; while for some other areas, a
multiple ascending dose (MAD) studymay serve as a PoC study. To avoid confusion, we refer to the smaller earlier study
as the Small Study, and the subsequent larger study as the Large Study throughout the article. There aremany reasons
the positive result observed in a Small Studymay not be replicated in the later Large Study. For example, the populations,
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duration, and endpoints between the two studiesmay be different. In oncology, the primary endpoint in a PoC study
is often progression-free survival, while the primary endpoint for a confirmatory study becomes overall survival. For
diabetes, glucosemay be investigated in a PoC study, while Hemoglobin A1c (HbA1c) is generally the primary endpoint
for a subsequent study. While these factors are important for consideration in evaluating the difference in the results
between the two studies or predicting the outcome in the Large Study based on the results from the Small Study, wewill
explore the fundamental reason for the difference in the estimation of the treatment effects between the two studies,
assuming they are similar except for the sample size.
It has been proposed that the probability of study success (PrSS) can account for the variability in the assumed
true treatment difference compared to the statistical power [7, 8]; However, statisticians often use a normal prior
distribution with the estimatedmean and variance from the Small Study (Frequentist approach), or use the posterior
distribution given the data in the Small Study with non-informative prior (Bayesian approach). This approach only
accounts for the variability from the Small Study, not the selection bias (only moving compounds with promising results
from the Small Study to the next development stage).
The problem of selection bias or regression to the mean was described as Tweedie’s formula [9, 10]. Tweedie’s
formula to estimate the prior density assumes the variance of measurement error was constant across observations.
Its application in clinical trials has not been widely realized. Chuang-Stein and Kirby described the phenomenon of
selection bias and regression to themean, and provided an overview of the research in discounting the early phase study
results [11]. One approach is to apply an empirical discount factor for the treatment effect or to raise the bar for the
criterion for moving the drug to the next development stage [12, 13]. Zhang evaluates the selection bias phenomenon
using a Bayesian approach assuming an informative prior distribution through simulation [14]. Again, the prior was used
as an empirical way of “discounting" the results from early phase studies with no clinical meaning and how to determine
the prior is not stated also in their paper.
In this article, wewill describe the aforementioned problem through a theoretical framework in the drug develop-
ment context, and build the connection between Frequentist and Bayesianmethods. Furthermore, wewill propose a
Bayesian hierarchical model to estimate the distribution for a portfolio of historical compounds, which can be used as
the prior for future drug development for treating the same disease with a similar mechanism. We envision that a very
important benefit of this research will be the improvement of probability of late phase study success and the reduction
of the overall cost of drug development.
This article is organized as follows. In Section 2, we provide the theoretical framework to explain the systematic
bias, introduced by the nature of the size of the Small Study, and the fact that we only select the promising compounds
moving forward. We also describe themethods to form a prior distribution used in the framework that characterizes the
treatment effect for a portfolio of similar compounds. In Section 3, we provide 2 data examples from drug development
in diabetes and rheumatoid arthritis (RA) disease respectively, using themethods described in Section 2. Finally, Section
4 provides a summary and discussion of the topic.
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2 | METHODS
Assume we are interested in estimating the treatment effect comparing a new treatment (at a certain dose) to a
comparator (typically placebo). The treatment effect can be the treatment difference inmeans or proportions, logarithm
of odds ratio, or logarithm of hazard ratio, depending on the type of variables for the outcome and study objectives.
Given a compound, let θ denote the true treatment effect. Without loss of generality, we assume a smaller value
of θ means better efficacy. Consider a typical sequential clinical development program for a compound in which an
exploratory Small Study is conducted first, and the subsequent Large Study is conducted upon promising results from
the Small Study. Assume the estimators of the treatment difference for the Small Study and Large Study are distributed
from
θˆS |θ ∼ FS (θ) (1)
and
θˆL |θ ∼ FL (θ), (2)
respectively. We further assume the compound being studied is from a portfolio of candidate treatments with the true
treatment effect distributed from
θ ∼ Fθ . (3)
We assume
1. θˆS ⊥ θˆL |θ, i.e., the conditional independence between θˆS and θˆL given the treatment effect θ for the compound
under investigation.
2. E [θˆS |θ] = E [θˆL |θ] = θ. Although sometimes the estimators are only asymptotically unbiased given θ, we assume
the conditional unbiasedness for the convenience of calculation and argumentation.
2.1 | The probability of observing a large treatment effect in a small PoC study
We now illustrate the impact of the variability in θˆS on the probability of meeting a desired threshold value for the
treatment difference through a normal prior distribution:
θˆS |θ ∼ N (θ,σ2s ).
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F IGURE 1 The distribution (density) of the true treatment effect (θ) and the estimator for the treatment effect in
the Small Study θˆS .
For example, suppose we intend to develop an anti-diabetes treatment and the primary endpoint in the Small
Study is the change in HbA1c from baseline at week 12. The desired treatment effect for the new treatment versus
placebo (difference in group means) is at least as good as δ = −1.5%. Figure 1 shows the relationship between the
probability of meeting the threshold value [Pr(θˆS ≤ δ)] and the standard deviation, σs , for θ ∼ N (−1.0, 0.5). We can see
that Pr(θˆS ≤ δ) increases as σs goes up. This means the smaller the sample size, themore likely wewould be to observe
a promising treatment effect for this particular compound in the portfolio.
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2.2 | Define and adjust for the selection bias from a frequentist approach
Although θˆS ⊥ θˆL |θ, an underlying distribution for θ imposes an unconditional correlation between θˆS and θˆL . A joint
distribution between θˆS and θˆL is shown below:
f (θˆS , θˆL ) =
∫
f (θˆS , θˆL , θ)dθ
=
∫
f (θˆS , θˆL |θ)f (θ)dθ
=
∫
f (θˆS |θ)f (θˆL |θ)f (θ)dθ. (4)
The conditional distribution f (θˆL |θˆS ) can subsequently be derived accordingly:
f (θˆL |θˆS ) = f (θˆS , θˆL )
f (θˆS )
. (5)
The drug development is a stage-wise process: we only move the compound to the Large Study if the Small Study shows
a reasonably promising result (e.g., θˆS < δ). Therefore, even though θˆL itself is an unbiased estimator for η, θˆL given
θˆS < δ is no longer an unbiased estimator for η.
We now evaluate two quantities of interest from the Small Study based on the conditional distribution:
1. Themean treatment difference for the Large Study conditional on the result from the Small Study, i.e., E (θˆL |θˆS ).
Since E (θˆL |θˆS ) is a function of θˆS , it has no selection bias. Therefore, E (θˆL |θˆS ) is an unbiased estimator for η, which
can be seen by E [E (θˆL |θˆS )] = E (θˆL ) = η.
2. The conditional probability of achieving the desired treatment effect for the Large Study conditional on the result
from the Small Study, i.e., Pr(θˆL < δ |θˆS ). It can also been seen that E {Pr(θˆL < δ |θˆS )} = Pr(θˆL < δ).
The bias (sometimes also called discount factor) for using θˆS to estimate the expected treatment effect for the Large
Study given the Small study is defined by
∆(θˆS ) = E (θˆL |θˆS ) − θˆS . (6)
The bias is computed based on the information from the Small Study and the information from the portfolio, but
independent of the estimate from the Large Study. It represents the amount of adjustment or discount factor we shall
apply to the treatment effect estimate from the Small Study in order to have a more realistic view of the expected
treatment effect from the Large Study.
To have amore concrete perspective on the definition of “bias", let us assume a special case where FS , FL , and Fθ
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F IGURE 2 The relationship between observed treatment effect in the Small Study (x-axis) and the difference in the
conditional treatment effect between the Large Study and Small Study (y-axis), assuming η = −1.0 and σ = 1.0.
are normal distributions such that
θˆS |θ ∼ N (θ,σ2S ), (7)
θˆL |θ ∼ N (θ,σ2L ), (8)
and
θ ∼ N (η,σ2), (9)
where η and σ2 are themean and variance for the prior distribution of θ. The unconditional distribution of (θˆS , θˆL ) is
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easily derived as
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The conditional distribution of θˆL given θˆS is
θˆL |θˆS = s ∼ N (η + (σ2S + σ2)−1σ2(s − η), (σ2L + σ2) − (σ2S + σ2)−1σ4). (11)
According to the definition by (6), the bias is given by
∆(s) = η + (σ2S + σ2)−1σ2(s − η) − s = (σ2S + σ2)−1σ2S (η − s). (12)
Figure 2 shows the bias related to the observed treatment effect in the Small Study for various sample sizes of the
Small Study. In this plot, wemimic the variable of the change in HbA1c in anti-diabetes drug development, assuming the
mean and standard deviation for the prior distribution are -1% and 1%, respectively. In anti-diabetes treatment PoC or
phase 2 studies, the sample size is generally between 20 and 100 per treatment arm. Since η is themean of a portfolio of
candidate drugs of the same class and the sponsors tend to pick up the compounds with promising results from the
Small Study tomove forward, s is generally smaller than η (keep in mind smaller values mean better efficacy). Then, the
bias is always positive, and the treatment effect observed in the Large Study is very likely worse than that in the Small
Study. Themore promising andmore variable the Small Study result is, the larger the difference between the expected
treatment effects from the 2 studies will be. Therefore, more discount shall be applied towards the observed treatment
effect in the Small Study in the planning of the next study, to offset themagnitude and variability in estimating θˆS .
The conditional distribution of θˆL given θˆS also enables us to estimate the probability of observing the desired
efficacy conditional on the result from the Small Study. Figure 3 depicts the relationship between the observed
treatment effect from the Small Study (θˆS ) and the conditional probability of the success of the Large Study for different
standard error of the observed treatment difference in the Small Study (with a similar setting as Figure 2). Again,
the more promising the observed treatment effect is in the Small Study, themore likely the next study is to succeed.
However, given any fixed value of θˆS , as the standard error of the estimate increases from 0.18 to 0.45, the conditional
probability of the success of the Large Study falls by 20-30%.
From (11), the adjusted estimator of the expected treatment effect for the Large Study is readily available:
E [θˆL |θˆS = s] = η + (σ2S + σ2)−1σ2(s − η).
Although it is called a special case when FS , FL , and Fθ are normal distributions, this is, in fact, quite general and
can apply to a wide variety of scenarios in clinical development. By central limit theorem, with moderate or large
QU, ET AL. 9
−2.0 −1.5 −1.0 −0.5 0.0
0.
0
0.
2
0.
4
0.
6
0.
8
θs
Pr
(θ L
 
<
 −
1.
5)
n = 20 ( σS=0.45 )
n = 40 ( σS=0.32 )
n = 80 ( σS=0.22 )
n = 120 ( σS=0.18 )
F IGURE 3 The relationship between the observed treatment difference estimate from the Small Study and the conditional
probability of the success of the subseqeunt Large Study (assuming η = −1.0, σ = 1.0, and the sample size is 400 for the Large
Study).
sample size, both θˆL and θˆS approximately follow normal distributions regardless of the distribution of their associated
outcomes. This is not very different from the estimation and inferences in the Frequentist approach, where the normal
approximation is commonly used. The only distribution that could be very non-Gaussian is the prior distribution Fθ ,
which depends on the nature of the portfolio of drugs under investigation.
2.3 | Understand and adjust for the bias from the perspective of Bayesian statistics
As Efron [10] pointed out, Bayesianmethod inherently prevents the bias if the appropriate prior distribution is used. Let
f (θ |θˆS ) be the posterior distribution given the estimator θˆS with a prior distribution of (3). The conditional expectation
E (θˆL |θˆS ) is equivalent to the Bayesian posterior mean for the Small Study with the prior distribution of (3). This can be
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seen by
E (θˆL |θˆS ) = E {E (θˆL |θˆS , θ) |θˆS } = E {E (θˆL |θ) |θˆS } = E (θ |θˆS ). (13)
Similarly,
Pr(θˆL < δ |θˆS ) = E {Pr(θˆL < δ |θˆS , θ) |θˆS } = E {Pr(θˆL < δ |θ) |θˆS } (14)
is the posterior expectation of E {Pr(θˆL < δ |θ)} given the estimator from the Small Study.
Often the sponsor who conducts the Small Study has the individual dataYS . Then, a fully Bayesianmethod based on
the observed data (instead of the estimator θˆS ) can be used to estimate the posterior distribution f (θ |YS ). The adjusted
point estimator is
E (θˆL |YS ) = E (θ |YS ), (15)
and the adjusted probability of meeting a threshold for the treatment effect is
Pr(θˆL < δ |YS ) = E {Pr(θˆL < δ |θ) |YS }. (16)
When the individual patient dataYS are available, the estimation based on the posterior distribution f (θ |YS ) ismore
natural, andmay bemore accurate compared to f (θ |θˆS )when the distribution of θˆS is not exactly normally distributed;
while the estimation based on the posterior distribution given θˆS provides an advantage when only the estimate for the
Small Study is available.
2.4 | Modeling the distribution of θ
The estimation of the distribution of θ is the key to the understanding of the portfolio performance in both Frequentist
and Bayesianmethods. In this section, wewill use a Bayesian hierarchical model to form the prior distribution.
Following up the special case in Section 2.2, the estimates of η and σ2 are required to carry out the bias adjustment
as defined by (12). We propose to construct a hierarchical model for the estimation of parameters η and σ2. At any
given point in time, we use the study data on the compound portfolio accumulated so far to infer the parameter of the
distribution of θ. As the portfolio is expanding with time, we should update the inference whenmore relevant study
information becomes available.
Suppose we have information for I compounds. For the i t h (1 ≤ i ≤ I ) compound, there aremi studies. Note that it
is important to include data from both positive and negative studies, and both early and late phase studies. For some
studies, the population, endpoint or study duration may be different from what we desire, either these studies are
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excluded or the treatment effect for the desired population, endpoint and study duration is estimatedwith additional
modeling and extrapolations. The estimates from the studies can bemodeled as
θˆi j |θi ∼ N (θi ,σ2i j ), i = 1, 2, . . . , I ; j = 1, 2, . . . ,mi (17)
and
θi ∼ N (η,σ2). (18)
By assigning prior distributions for η and σ2, the inference on η and σ2 can be easily obtained from themaximum
likelihood estimation or using Bayesian hierarchical modeling framework. Note Tweedie’s formula cannot be used
here as the variances σ2
i j
are not constant [9, 10]. We suggest a non-informative or weakly informative prior for the
distribution of η and σ2 , where for example, η ∼ N (0, 1000);σ2 ∼ Inverse Gamma (0.001, 0.001). Standard softwares are
readily available to draw the posterior inference based on the defined hierarchical modeling, such as JAGS,WinBUGS
and STAN. Once the posterior estimates for η and σ2 are obtained, they can be fed into (12) to gauge the bias for any
compound in the portfolio finishing the Small Study with a promising result, and construct an adjusted estimator for the
assessment of efficacy of this compound and planning for the next study.
Themethod of estimating Fθ can be easily generalized to othermodels or assuming a non-Gaussian distribution.
For example, a more complex approach tomodel the prior is to include the within-compound between-study variability.
Specifically, one can replace equation (17) with
θˆi j |θi j ∼ N (θi j ,σ2i j ), θi j |θi ∼ N (θi ,σ2i ), i = 1, 2, . . . , I ; j = 1, 2, . . . ,mi , (19)
where θi j themean for study j and compound i , σ2i j is the variance of θˆi j given θi j , θi is themean for compound i , and
σ2
i
is the between-study variance for compound i . In some cases it may be difficult to estimate thewithin-compound
between-study variability when there is only 1 Small Study for a compound.
3 | REAL DATA EXAMPLES
In this section, we illustrate the application of bias adjustment through real data examples in two therapeutic areas:
diabetes and immunology. In the diabetes therapeutic area, we considered the endpoint of body weight for the class of
incretins as anti-diabetic drugs for patients with Type-2 diabetes while in the immunology therapeutic area, we focused
on the treatment against the disease of rheumatoid arthritis (RA).
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3.1 | Diabetes Therapeutic Area
Due to confidentiality requirements, the compounds have been de-identified. The proposed method in Section 2.4
is implemented tomodel the distribution of the treatment effect θ in the portfolio of candidate compounds. To that
purpose, we gathered and used the available study data (from publication or conference presentations) with regards to
the effect of incretins onweight loss across pharmaceutical companies. In this real data application, the Small Study
refers to the phase 1bMAD studywhile the Large Study corresponds to the phase 2 study. Again, we assume normal
distributions for FS , FL , and Fθ . In this illustrative example, the outcome is the change in body weight from baseline to
4 weeks. There are 5 compounds for which we know the estimates and their standard errors for both phase 1b and
phase 2 studies, so that we can compare the bias-adjusted estimate and the observed treatment effect in phase 2 study.
In all studies for all 5 compounds, the population was similar: patients with Type-2 diabetes with inadequate glycemic
control by diet and exercise or the treatment of metformin. The application follows the below procedure:
1. Use themethod in Section 2.4 tomodel the distribution Fθ with all available information.
2. Apply the bias adjustment as in (12) to those 5 compounds, compute the new estimate E [θˆL |θˆS = s], and compare
with the observed treatment effect for the phase 2 study.
The actual availability of the Large Study (phase 2 study) results allow for a comparison of the un-adjusted and
adjusted estimates (θˆS and E [θˆL |θˆS = s], respectively) with the observed estimates of treatment effect in phase 2
study. Figure 4 shows a graphical display of the unadjusted treatment effect based on the Small Study (θˆS ) versus the
observed treatment effect in the Large Study (solid circles), and the adjusted treatment effect based on the Small Study
(E [θˆL |θˆS = s]) versus the observed treatment effect in the Large Study (hollow circle) for all 5 incretin compounds. The
circle size (area) is proportionate to the information of the estimates (i.e., one over the square of the standard error).
Most data used in this figure are confidential and have not been published, so we removed the scales for the x-axis and
y-axis. For the illustration of effectiveness of the bias adjustment, the relative, but not the absolute scale, is sufficient.
Ideally, we expect the solid circles (unadjusted estimates) to be distributed symmetrically across the 45-degree line;
however, most of the time the sponsors are only willing tomove the compounds to the next developmental stage when
they exhibit promising results in the Small Study. This results in an uneven distribution of the solid circles withmore
circles in the lower right quadrant and fewer circles in the upper left area, a phenomenon of selection bias.
The adjusted estimates are closer to the observed treatment effect in phase 2 studies, as indicated by all the hollow
circles with the exception of the purple compoundmoving away from the 45-degree line. This is not surprising because
both the adjusted estimates from phase 1b studies (also called Bayesian shrinkage estimates) and the unadjusted
estimate from phase 2b studies were subject to variability and, more importantly the Bayesian shrinkage estimator
provides better overall estimation (e.g., in terms of mean squared errors) but may be biased if conditional on individual
compounds. The estimate for the orange compound had relatively large variance for the treatment effect estimate
(as indicated by a small circle) and a large treatment effect (much more than η). Therefore, the circle for the orange
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F IGURE 4 The application of the bias adjustment in estimating the treatment effect on the change in bodyweight from
baseline to 4weeks for anti-diabetic incretin drugs. The x-axis for the solid circle indicates observed (unadjusted) treatment
effect in Small Study and the x-axis for the hollow circle indicates adjusted treatment effect in Small Study.
compound had themost shift to the left. On the other hand, there was also one compound (the leftmost) with almost
no weight loss based on the phase 1b study, while someweight loss was observed in a subsequent Large Study. This
is rare in practice but it is possible for several reasons, for example, the primary outcome uponwhich the decision is
mademay not beweight loss. In addition, Figure 4 shows the adjustmentmay not alwaysmake the treatment effect
smaller. For the 2 leftmost compounds, the adjusted treatment effect was larger compared to the unadjusted one. This
phenomenon is consistent with the property of the Bayesian shrinkage estimator, which shrinks the estimates to the
center of the prior distribution.
3.2 | Immunology Therapeutic Area
In this section, we further illustrate how the bias-adjusting method could be implemented in an RA example. While
there are a handful of compounds approved for RA, it is not uncommon that a compoundwhich is promising in a phase 2
study fails in phase 3. In this example, the Small Study refers to the phase 2while the Large Study corresponds to the
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phase 3 study. The outcome is set to be ACR20 (whether a patient has ≥ 20% improvement in ACR [American College
of Rheumatology] assessment) at week 12, and the treatment effect θ is defined as the difference in ACR20 response
rates between an experimental treatment and placebo arms. As treatment effect varies significantly across different
subpopulations, we only focus on studies with populations that have had an inadequate response to methotrexate
(MTX). As previously mentioned, normal distributions for FS , FL , and Fθ are assumed throughout this section.
To estimate the portfolio distribution of θ ∼ N (η,σ2), we perform a systematic review of literature and select
RA clinical trials based on two criteria: (i) double-blind, placebo-controlled RA trials with ACR20 results reported at
week 12; (ii) > 50%of enrolled patients have inadequate-response toMTX. Ultimately, 48 phase 2 trials are selected.
We apply themethod in Section 2.4 using published estimates and standard errors in the selected phase 2 trials. The
prior distribution is therefore estimated such that θ ∼ N (0.244, 0.142), which is then used to calculate the adjusted
treatment effect E [θˆL |θˆS = s]. Fourteen out of 48 phase 2 trials have been corresponded to 15 phase 3 trials, all of
which share similar population and background therapies as those in selected phase 2 trials. Note that a phase 2 trial
may be matched with more than one phase 3 trials. In this case, we used the meta-analysis to pool the results from
multiple phase 3 trials and treated as one large phase 3 study. Overall, therewere 9 compounds and 24 compound-dose
levels (“treatments") included in the analysis.
Figure 5 represents the unadjusted treatment effect θˆS based on the phase 2 study versus the observed treatment
effect in the phase 3 study (solid circles), and the adjusted treatment effect based on the phase 2 study E [θˆL |θˆS = s]
versus the observed treatment effect in the phase 3 study (hollow circle). Each circle represents 1 compound-dose
level. The circle size (area) is proportionate to the information of the estimates (i.e., one over the square of the standard
error). The observed treatment effects θˆS in phase 2 range from 0.1 to 0.75, while phase 3 results aremore stable and
treatment effects θˆL are within the range 0.2 to 0.4. Again, most of the solid circles fall under the 45-degree line, which
means that in general phase 3 results appear worse than originally reported phase 2 results. This is another example
of selection bias. Compared to the observed phase 2 treatment difference estimator θˆS , the bias-adjusted estimator
E [θˆL |θˆS = s] is closer to its observed phase 3 results θˆL . The plot also shows themagnitude of bias-adjustment through
the length of the arrow between each pair of solid and hollow circles. The longer the arrow, themore bias-adjustment is
present. Such bias-adjustment is associated with two terms: (i) difference between η and the observed phase 2 result
θˆS : the closer the observed phase 2 results are to 0.244, the smaller adjustment shall be applied; (ii) phase 2 sample size:
larger phase 2 sample size leads to a smaller adjustment, as indicated in (13).
4 | SUMMARY AND DISCUSSION
Selection bias or regression to themean phenomenon has been observed in the past, and some research has been done
in this area. In this article, wemade new contributions in four aspects: the clinical meaning of the prior, the connection
between the estimation bias due to selection bias and the Bayesian posterior mean, the use of hierarchical modeling to
estimate the distribution of the underlying treatment effect for a portfolio of compounds, which can be used as the
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F IGURE 5 The application of the bias adjustment in estimating the treatment effect of selected RA compounds. The x-axis
for the solid circle indicates observed (unadjusted) treatment effect in Small Study and the x-axis for the hollow circle indicates
adjusted treatment effect in Small Study.
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prior distribution to adjust the treatment effect for current and future studies, and the role of estimation variability in
the Small Study in the estimation bias.
Although prior distribution has been used in the estimation of posterior mean to account for selection bias, the
clinical meaning of prior distributionwas not clearly defined [14]. In this article, we defined that the prior represents
the distribution of the underlying treatment effect of a portfolio of similar compounds. The clarification of the clinical
meaning of prior distribution allows us to develop a Bayesian hierarchical model to estimate the prior distribution. We
start from the commonly understood bias asE [θˆL |θˆS ]− θˆS and showed this is equivalent toE [θ |θˆS ]− θˆS , the “regression
to themean" (discount) effect from the Bayeisan framework, if θ is the treatment effect. While Chuang-Stein and Kirty
consider the discount based on the Bayesian framework as a different definition of “regression to themean" [11], we
established the equivalence of discount between Frequentist and Bayesianmethods. We also further quantified the
variability in the estimator for the Small Study on the probability of achieving a large promising treatment effect, as well
as on the bias. The larger the estimation variability and the larger the effect size in the Small Study, themore discount
should be applied to adjust for the bias in the estimator for the Large Study. Therefore, special caution should be taken
when a very promising signal is observed from a very small study.
This phenomenon may be perplexing. For a single asset, θˆS , the estimator from the Small Study, is unbiased for
treatment effect since E (θˆS |θ) = θ. However, from a portfolio perspective, the distribution of the observed treatment
effect θˆS is more variable than the distribution of true θ, but θˆS is still an unbiased estimator for the mean of true
treatment effect for the portfolio. This can be seen from the theoretical perspective:
V ar (θˆS ) = E [V ar (θˆS |θ)] +V ar [E (θˆS |θ)] = E [V ar (θˆS |θ)] +V ar (θ) > V ar (θ)
and
E (θˆS ) = E [E (θˆS |θ)] = E [θ].
ABayesian shrinkage estimator will provide amore realistic estimation of the distribution of θ. When only promising
compounds (e.g., θˆS < δ) based on the Small Study aremoved forward for the next stage of development, a selection
bias is introduced. In the presence of such selection bias, θˆS is also biased for θ. This can be seen by
E (θˆS |θˆS < δ) , E (θ).
In this article, we provided two examples with the treatment effects being the difference in means and difference in
proportions and a normal prior. The theoretical framework in this article can be applied to other contrasts of treatment
effect (e.g., logarithm of the odds ratio or logarithm of the hazard ratio), since all these estimators approximately
follow normal distribution. The prior distribution for θ does not have to be a normal distribution. For example, the
prior distribution may be a mixture of two normal distributions representing two sets of compounds with little and
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reasonable treatment effect respectively, or contain amass on the treatment effect of zero to account for drugs with
no treatment effect. Selection of studies/compounds to form the prior distribution Fθ is important in application of
the proposed method to adjust for the selection bias. For a new compound that is not novel (i.e., data are available
for similar compounds), the data from compounds in the same or similar class should be used to form the prior. For a
compoundwith a novel target (i.e., no data are available for similar compounds), wemay assume this compound comes
from a distribution of existing classes of treatments. For such compounds, a prior distribution to characterize different
classes of treatments for the same disease can be used: either a prior constructed by treating each class as one data
point (mean treatment effect for each class based on meta-analysis) as described in Equation (17) or a hierarchical
model considering the between-study, compound and class variabilities [e.g., Equation (19)].
In addition to sample size, there may be many differences between Small and Large Studies, including but not
limited to population, endpoint, duration, and dose. In this article, we proposed amethod to predict mean treatment
effect of Large Study based on Small Study in consideration of adjusting for the selection bias only, assuming Small and
Large Studies are otherwise similar except for sample size. Althoughwe generally try tomake phase 2 studies more
translatable to phase 3 studies, considerable differencemay still exist between phase 2 and 3 studies, possibly due to
the safety consideration, limited knowledge on the candidate treatment, and financial consideration. In this case, one
should take a 2-step approach for predicting the treatment effect of the candidate treatment in phase 3 studies. First, a
model to account for the differences between phase 2 and 3 studies should be built to predict phase 3 results without
adjusting for the selection bias. Then, themethod proposed in this article can be applied to the predicted outcome in
Step 1 to adjust for the selection bias. The predictionmodel as well as the prior for adjusting for selection bias should be
pre-specified and developed before the completion of Small Study so that (1) the predictionmodel and the prior can be
agreed upon before knowing the Small study results to avoid bias due to subjectivity, and (2) the adjusted treatment
effect can be estimated expeditiously right after the Small Study results become available.
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